Current stock value

Last updated on May 28, 2015 4:00 PM ET

NASDAQ : SPHS 1.11   
+ 0.03

Investor Presentation

PDF Download the Sophiris Investor Presentation


Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of BPH and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris plans to initiate a Phase 2 proof of concept study of PRX302 for the treatment of localized low to intermediate risk prostate cancer during the first half of 2015.

View all »   RSSRecent Releases

May 27, 2015
Sophiris Bio to Present at the LD Micro Invitational Conference

May 26, 2015
Sophiris Bio Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study

View all »Events & Presentations

Jun 2, 2015 at 11:30 AM PT
LD Micro Invitational Conference